Tips from the APSHO Experts

Clinical pearls from leading advanced practitioners from the JADPRO Live at APSHO conference


Search by:

How do I manage infusion reactions?

Jeffrey Jones, MD, MPH
The James Cancer Hospital at The Ohio State University

Mollie Moran, CNP
Ohio State University Comprehensive Cancer Center

Watch Video


Main Session: Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

At what point does a patient become a candidate for treatment with CDK inhibitors?

Lee S. Schwartzberg, MD, FACP
West Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

What do APs need to know about hematologic side effects and how to manage them?

Lee S. Schwartzberg, MD, FACP
West Cancer Center

Heather Greene, MSN, FNP, AOCNP
West Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

What are the most common side effects of CDK inhibitors?

Heather Greene, MSN, FNP, AOCNP
West Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

What role do HER2 and VEGF monoclonal antibodies have in treating gastric cancer?

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Gastric Cancer

What are the most important takeaway messages for APs in the care of patients with gastric cancer?

Steven Malangone, MSN, FNP-BC, AOCNP
University of Arizona Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Gastric Cancer

Is there a role for neoadjuvant treatment in gastric and esophageal cancer?

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center

Watch Video


Main Session: Collaborative Management of Patients with Gastric Cancer

What is the best way to monitor CLL patients?

Mollie Moran, CNP
Ohio State University Comprehensive Cancer Center

Watch Video


Main Session: Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

What do the NCCN Guidelines recommend for diagnostic workup and risk assessment in patients with newly diagnosed CLL?

Jeffrey Jones, MD, MPH
The James Cancer Hospital at The Ohio State University

Watch Video


Main Session: Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

What are the symptoms of cytokine-release syndrome, and what is the best treatment?

Patricia Mangan, CRNP
Abramson Cancer Center, University of Pennsylvania

Watch Video


Main Session: Understanding the Mechanism of Action for Chimeric Antigen Receptor (CAR) Therapy

What role does the AP play in recommending/explaining to patients their treatment options?

Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP
Stanford Cancer Center

Watch Video


Main Session: Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

How do biosimilars differ from generic drugs?

James S. Lewis, PharmD, FIDSA
Oregon Health and Science University

Watch Video


Main Session: Best Practices in the Management of Infectious Complications for Patients with Cancer

What are the risk factors for developing febrile or prolonged neutropenia?

James S. Lewis, PharmD, FIDSA
Oregon Health and Science University

Watch Video


Main Session: Best Practices in the Management of Infectious Complications for Patients with Cancer

What are the unique side effects associated with venetoclax?

Michelle R. Wisniewski, MS, PA-C
Memorial Sloan Kettering Cancer Center

Watch Video


Main Session: Nuances in the Management of Aggressive Lymphomas

What is the role of immunotherapy in aggressive lymphoma? What do APs need to know about managing immune-related adverse events in patients?

Paul Hamlin, MD
Memorial Sloan Kettering Cancer Center

Michelle R. Wisniewski, MS, PA-C
Memorial Sloan Kettering Cancer Center

Watch Video


Main Session: Nuances in the Management of Aggressive Lymphomas

How does genetic information affect treatment decisions in aggressive lymphoma, such as DLBCL?

Paul Hamlin, MD
Memorial Sloan Kettering Cancer Center

Watch Video


Main Session: Nuances in the Management of Aggressive Lymphomas

What are some of the non-pharmacologic interventions that you find helpful?

Sally Yowell Barbour, PharmD, BCOP, CPP
Duke University Hospital

Watch Video


Main Session: Management of Patients with Chemotherapy - Induced Nausea and Vomiting

How do you prevent the side effects of emetogenic chemotherapy agents?

Sally Yowell Barbour, PharmD, BCOP, CPP
Duke University Hospital

Watch Video


Main Session: Management of Patients with Chemotherapy - Induced Nausea and Vomiting

What do APs need to know about mutational/molecular testing?

Millie Das, MD
Stanford University and VA Palo Alto

Watch Video


Main Session: Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

How is CAR T-cell therapy delivered?

Edward A. Stadtmauer, MD
Abramson Cancer Center, University of Pennsylvania

Watch Video


Main Session: Understanding the Mechanism of Action for Chimeric Antigen Receptor (CAR) Therapy

What are the mechanisms of action of the new and emerging agents for multiple myeloma?

Jonathan Kaufman, MD
The Winship Cancer Institute of Emory University

Watch Video


Main Session: New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

What are some of the challenges of multimodality therapy for patients and APs?

Jason Glass, ACNP-BC
Dana-Farber Cancer Institute

Watch Video


Main Session: Advances in Collaborative Practice for Patients with Head and Neck Cancers

What is the role of the AP on a multidisciplinary team caring for patients with head and neck cancer?

Jason Glass, ACNP-BC
Dana-Farber Cancer Institute

Watch Video


Main Session: Advances in Collaborative Practice for Patients with Head and Neck Cancers

What do NCCN guidelines say about anticoagulants and when they should be used?

Rowena Schwartz, PharmD, BCOP
University of Cincinnati

Watch Video


Main Session: Management of Venous Thromboembolism for Patients with Hematologic Malignancies

What are the main risk factors for VTE in cancer patients?

Rowena Schwartz, PharmD, BCOP
University of Cincinnati

Watch Video


Main Session: Management of Venous Thromboembolism for Patients with Hematologic Malignancies

What are the toxicities associated with the agents used for multiple myeloma?

Charise Gleason, MSN, NP-BC, AOCNP
The Winship Cancer Institute of Emory University

Watch Video


Main Session: New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

What do you need to know to create an optimal treatment regimen for the individual patient?

Jonathan Kaufman, MD
The Winship Cancer Institute of Emory University

Charise Gleason, MSN, NP-BC, AOCNP
The Winship Cancer Institute of Emory University

Watch Video


Main Session: New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

What do APs need to know about the sonic hedgehog signaling pathway?

Daniel Siegel, MD, FAAD, FACMS
SUNY Downstate Medical Center, Department of Dermatology

Watch Video


Main Session: Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma

What do APs need to know about optimal immunotherapy treatments?

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center

Laura Zitella, MS, RN, ACNP-BC, AOCN
Stanford Cancer Institute

Watch Video


Main Session: Immunotherapy: Advances and Updates

How do I know a patient will respond to immunotherapy?

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center

Watch Video


Main Session: Immunotherapy: Advances and Updates

How can immune-related adverse events be managed?

Brianna Hoffner, MS, ANP-BC, AOCNP
Univ of Colorado Cancer Center

Watch Video


Main Session: Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma

What do I need to know about the best possible treatment regimen for each patient? How do I explain to patients the risks and benefits of their choices?

Joseph M. Herman, MD
University of Texas MD Anderson Cancer Center

Amy Hacker-Prietz, PA-C
Johns Hopkins University

Watch Video


Main Session: What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

What are the risk factors for pancreatic cancer?

Joseph M. Herman, MD
University of Texas MD Anderson Cancer Center

Watch Video


Main Session: What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

How can I help improve quality of life in my patients with pancreatic cancer?

Amy Hacker-Prietz, PA-C
Johns Hopkins University

Watch Video


Main Session: What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

What adverse effects are associated with somatostatin analog treatments?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What is carcinoid syndrome?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What is the evidence from the PROMID and CLARINET clinical trials for use of somatostatin analogs in patients who do not have hormonal symptoms?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What do the NCCN guidelines recommended for diagnostic testing in patients being treated for pancreatic neuroendocrine tumors (pNET)?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

Can you give us an overview of the classification system of neuroendocrine tumors and its significance?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What are important considerations for APs in the management of side effects in patients being treated for mCRC?

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute

Watch Video


Main Session: Updates in the Treatment of Metastatic Colorectal Cancer

What should advanced practitioners look for with CLL patients that also have lymphocytosis?

Amy L. Goodrich, MSN, CRNP
Johns Hopkins University

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

What test should an advanced practitioner order if CLL is suspected?

Amy L. Goodrich, MSN, CRNP
Johns Hopkins University

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

What are the differences in the side effect profile between the monoclonal antibody treatments for CLL?

Amy L. Goodrich, MSN, CRNP
Johns Hopkins University

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

What elements should be included in the education of patient and families receiving dinutuximab therapy?

Rhonda McDougall, PNP
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What is the importance of an interprofessional approach in the management of a patient receiving dinutuximab therapy?

Rhonda McDougall, PNP
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

In the era of high response rates seen in immunotherapy combinations and targeted therapy combinations, how do you sequence therapies?

Brianna Hoffner, MS, ANP-BC, AOCNP
The Angeles Clinic and Research Institute

Watch Video


Main Session: Evolving Paradigms in Melanoma Therapy

Do you have any practical "take-away" clinical tips for APs in the community setting caring for melanoma patients on immunotherapy?

Brianna Hoffner, MS, ANP-BC, AOCNP
The Angeles Clinic and Research Institute

Watch Video


Main Session: Evolving Paradigms in Melanoma Therapy

How do immune-related adverse events differ from toxicities seen in targeted or chemotherapies?

Brianna Hoffner, MS, ANP-BC, AOCNP
The Angeles Clinic and Research Institute

Watch Video


Main Session: Evolving Paradigms in Melanoma Therapy

How does the combination of CTLA-4 and PD-1 agents enhance treatment outcomes for melanoma patients?

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center

Watch Video


Main Session: Evolving Paradigms in Melanoma Therapy

How should biomarkers for CTLA-4 and PD-L1 be integrated in patients with melanoma?

Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center

Watch Video


Main Session: Evolving Paradigms in Melanoma Therapy

What are the most important prognostic factors in CLL?

Deborah M. Stephens, DO
Huntsman Cancer Institute

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

How does Bruton's tyrosine kinase differ from other tyrosine kinases, and what role does it play in CLL and treatment?

Deborah M. Stephens, DO
Huntsman Cancer Institute

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

The monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target CD20; how do they differ in their indications in the treatment of CLL?

Deborah M. Stephens, DO
Huntsman Cancer Institute

Watch Video


Main Session: Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

How do you identify a patient with high-risk neuroblastoma?

Rajen Mody, MD, MS
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What is the mechanism of action for dinutuximab?

Rajen Mody, MD, MS
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What are the biggest challenges of managing high-risk neuroblastoma?

Rajen Mody, MD, MS
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What comorbidities should be taken into account before dosing with dinutuximab?

Erika Mora, PharmD
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What are the black box warnings for dinutuximab?

Erika Mora, PharmD
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

For patients with neuroblastoma receiving immunotherapy, what pharmacologic treatment should be considered for pain management?

Erika Mora, PharmD
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

Why is an interprofessional approach and family centered care important to patients receiving this immunotherapy?

Elizabeth Hollenkamp, BSN, RN
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

Why is pain viewed as a biopsychosocial phenomenon?

Elizabeth Hollenkamp, BSN, RN
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What are some modalities that can reduce or eliminate pain-associated suffering?

Elizabeth Hollenkamp, BSN, RN
University of Michigan

Watch Video


Main Session: Immunotherapy for High-Risk Neuroblastoma

What is the difference between a biologic and a biosimilar?

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

Watch Video


Main Session: The Science Behind Biologics and Biosimilars

What should be taken into consideration about the manufacture of biosimilars?

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

Watch Video


Main Session: The Science Behind Biologics and Biosimilars

How will biosimilars hopefully improve patient access to treatment?

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

Watch Video


Main Session: The Science Behind Biologics and Biosimilars

How do you decide if you're going to prescribe a biosimilar to your patients?

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

Watch Video


Main Session: The Science Behind Biologics and Biosimilars

Are biosimilars interchangeable?

Kelley D. Mayden, MSN, FNP, AOCNP
Wellmont Cancer Institute

Watch Video


Main Session: The Science Behind Biologics and Biosimilars

How do IMIDs work?

Craig B. Reeder, MD
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?

Craig B. Reeder, MD
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.

Craig B. Reeder, MD
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

What are the toxicities associated with the agents used for multiple myeloma?

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

What are some monitoring parameters for toxicities to establish?

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

How can I increase patient adherence to treatment regimens for multiple myeloma?

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Watch Video


Main Session: Risk Stratification in Multiple Myeloma

What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?

R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University

Watch Video


Main Session: Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What should pharmacists know about combining treatment agents for patients with NSCLC?

R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University

Watch Video


Main Session: Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What types of symptoms do patients diagnosed with a neuroendocrine tumor have?

Jennifer A. Chan, MD, MPH
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What is a neuroendocrine tumor?

Jennifer A. Chan, MD, MPH
Dana-Farber Cancer Institute

Watch Video


Main Session: Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

What are PD-1 and PD-L1?

Suzanne Walker, CRNP, MSN, AOCN, BC
Abramson Cancer Center at Penn-Presbyterian Medical Center

Watch Video


Main Session: Non-Small Cell Lung Cancer: Immunotherapy

How does the side effect profile of immunotherapies compare with that of standard chemotherapy, and which therapy are your patients tolerating better?

Suzanne Walker, CRNP, MSN, AOCN, BC
Abramson Cancer Center at Penn-Presbyterian Medical Center

Watch Video


Main Session: Non-Small Cell Lung Cancer: Immunotherapy

Does resistance occur with immunotherapy in oncology?

Suzanne Walker, CRNP, MSN, AOCN, BC
Abramson Cancer Center at Penn-Presbyterian Medical Center

Watch Video


Main Session: Non-Small Cell Lung Cancer: Immunotherapy

What is the best way to combine immunotherapy with traditional cytotoxic chemotherapy?

Suzanne Walker, CRNP, MSN, AOCN, BC
Abramson Cancer Center at Penn-Presbyterian Medical Center

Watch Video


Main Session: Non-Small Cell Lung Cancer: Immunotherapy

What is the role of EGFR mutations in patients with NSCLC?

Sukhmani K. Padda, MD
Stanford Cancer Institute

Watch Video


Main Session: Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What is T790m and describe its role in drug resistance?

Sukhmani K. Padda, MD
Stanford Cancer Institute

Watch Video


Main Session: Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What is ALK and how does it impact the treatment of NSCLC?

Sukhmani K. Padda, MD
Stanford Cancer Institute

Watch Video


Main Session: Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What guidance would you offer advanced practitioners caring for patients with refractory CINV? What about drug interactions?

Wendy Smith, RN, MSN, ACNP, AOCN
Meniscus Educational Institute

Watch Video

How do you optimize patient outcomes when adverse events occur?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

What should you be aware of when monitoring for toxicities linked with newer agents?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

What are some of the emerging therapies and their mechanisms of action?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What is the role of the advanced practitioner in the cancer care team?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What are the best ways to help patients adhere to oral therapies?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

How do you select and sequence treatments in the upfront and relapsed/refractory settings?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What are some of the emerging therapies and their mechanisms of action?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What should you be aware of when monitoring for toxicities linked with newer agents?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me